Core Insights - HeartSciences Inc. has announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category, marking a significant milestone in its interoperability strategy [1][3]. Group 1: Product Overview - MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making [2]. - The platform integrates with hospital information systems and electronic health records (EHRs), including Epic, through HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR [2]. - MyoVista Insights is device-agnostic and aims to improve clinical efficiency and decision-making through the integration of artificial intelligence (AI) [5]. Group 2: Strategic Importance - The Epic Toolbox designation is part of HeartSciences' strategy to enable seamless integration of MyoVista Insights into clinical workflows and expand access across healthcare systems [3]. - The company emphasizes the importance of interoperability in enhancing the usability of its platform within existing clinical workflows [3].

Core Viewpoint - HeartSciences Inc. is advancing its MyoVista Insights™ healthcare IT platform and has submitted its MyoVista® wavECG™ device for FDA clearance, aiming to modernize ECG through AI integration [1][6]. Financial Results - The company reported no meaningful revenue for the fiscal third quarter ended January 31, 2026, as it focuses on the commercialization of the MyoVista Insights platform [6]. - As of January 31, 2026, HeartSciences had approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders' equity [7]. Product Development - HeartSciences is advancing the commercialization of its MyoVista Insights platform and has submitted the MyoVista wavECG device to the FDA for 510(k) premarket clearance [2][4]. - The MyoVista Insights platform is classified as a Medical Device Data System (MDDS), which allows for a faster and less costly commercial rollout compared to regulated medical devices [5]. Management Commentary - The CEO highlighted strong progress towards 2026 objectives, including establishing reference sites and generating revenue for MyoVista Insights [5]. - The company has received compelling early feedback and is in discussions with multiple health systems regarding deployment [5]. Market Opportunity - MyoVista Insights is designed to enable the integration of AI-ECG algorithms into clinical practice, positioning HeartSciences to participate in a multi-billion-dollar AI-ECG market opportunity [5]. - The platform aims to host third-party algorithms alongside its own technologies, reducing costs and time for algorithm development and regulatory clearance [5]. Upcoming Events - Following the public introduction of MyoVista Insights at the ACC Annual Scientific Session, the company plans to host an investor call to demonstrate the platform and discuss its commercialization strategy [5].

Core Viewpoint - HeartSciences Inc. has partnered with Cibolo Rural Health Networks to provide its MyoVista Insights™ ECG management platform to a network of 123 independent hospitals, enhancing ECG workflow efficiency and clinical decision-making [1][2][4]. Group 1: Company Overview - HeartSciences is a healthcare information technology company focused on advancing electrocardiography through artificial intelligence integration [1][5]. - The MyoVista Insights platform is a cloud-native ECG management system designed to improve clinical efficiency and decision-making [5]. Group 2: Partnership Details - Cibolo Health has selected MyoVista Insights as its endorsed ECG management platform for its network of independent hospitals across six states [2][4]. - The collaboration aims to modernize legacy ECG workflows, allowing physicians to interpret ECGs more quickly and efficiently [2][4]. Group 3: Technology and Benefits - MyoVista Insights provides secure, cloud-based ECG data management across various devices and file formats, supporting the integration of AI-ECG algorithms into clinical practice [3]. - The partnership aligns with Cibolo Health's mission to enhance care quality and operational efficiency while managing costs for its member hospitals [4][6].

Core Viewpoint - HeartSciences Inc. is advancing its MyoVista Insights™ healthcare IT platform and has submitted its MyoVista® wavECG™ device for FDA clearance, marking significant progress in the commercialization of its ECG technology [1][2][5]. Group 1: Business Developments - The Company has made substantial advancements in the commercialization of its MyoVista Insights™ platform and has submitted the MyoVista® wavECG™ device to the FDA for 510(k) premarket clearance [2][5]. - MyoVista Insights is classified as a Medical Device Data System (MDDS), which allows for a faster and less costly commercial rollout compared to regulated medical devices [7]. - The platform has received strong validation from early adopters and is currently in commercial discussions with several healthcare institutions, with expectations to announce key customer wins soon [5][7]. Group 2: Financial Results - HeartSciences reported no meaningful revenue for the fiscal second quarter ended October 31, 2025, and had approximately $2.0 million in cash and cash equivalents, along with $4.2 million in shareholders' equity [8]. Group 3: Market Opportunity - The MyoVista Insights platform is designed to host third-party AI-ECG algorithms, positioning the Company to capture a multibillion-dollar market opportunity while reducing costs and time for algorithm development and regulatory clearance [7]. - The Company plans to host an investor call early in the new year to demonstrate the MyoVista Insights software and discuss its commercialization strategy and market opportunity [7].

Core Insights - HeartSciences Inc. has announced the commercial release of MyoVista Insights™ version 1.1, enhancing usability and clinical interpretation capabilities of ECG systems [1][2] - The platform is designed to improve workflow efficiency and expand interoperability across various ECG devices, making it a vendor and device agnostic solution [2][3] Product Features - MyoVista Insights is a cloud-native ECG management system that integrates AI ECG algorithm models from multiple partners, streamlining data management and improving workflow efficiency [2] - The updated version 1.1 provides a more intuitive platform for cardiac care, allowing clinicians to quickly interpret complex ECG data and make informed decisions [3] Market Position - Since its launch in May 2025, MyoVista Insights has received strong validation from early adopters and is currently in commercial discussions with several leading healthcare institutions [2] - The company aims to announce key customer deployments in the near term, indicating a positive market reception and potential growth opportunities [2]